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Summary
The fight to effectively treat and stop the spread of the human immunodeficiency virus
(HIV) has made meaningful progress both in the United States and globally. But within
the United States that progress has been uneven across various demographic groups and
geographic areas, and has plateaued. While scientific advances have led to the
development of medicine capable of both treating and preventing HIV, law and policy
dictate who will have ready access to these medicines and other prevention techniques,
and who will not. Law and policy also play a crucial role in determining whether HIV will
be stigmatized, discouraging people from being tested and treated, or will be identified
for what it is—a preventable and treatable disease. To make further progress against HIV,
the United States must address healthcare disparities, end the criminalization of HIV, and
devote additional resources toward combatting HIV stigma and discrimination.
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Uneven Progress in the Fight Against HIV
According to Centers for Disease Control (CDC) estimates available in mid 2019, over 1.1
million people in the United States are living with HIV, with around one million people
1
diagnosed with HIV. This means about 1 in 7 people living with HIV are unaware that they
have the disease (CDC, 2019a; DHHS, 2020). In total, around 700,000 people have died from
HIV/AIDS in the United States since the start of the epidemic in the 1980s. While the annual
incidence of new HIV infection had been steadily decreasing, beginning in around 2013, the
number of estimated new infections began to level off at around 38,000 to 39,000 per year
(CDC, 2019a; DHHS, 2020). This plateau persists because effective prevention and treatment
efforts are not reaching certain populations, in part because of persistent stigma and
discrimination. In other words, the impact of the disease continues to be unevenly distributed,
with higher concentrations among certain racial and sexual minorities (CDC, 2018a, 2020a).
Overall, black people have the highest rate of HIV prevalence (the number of people living
with HIV) as compared to other racial and ethnic groups, and the rate of new infection among
black people continues to be disproportionately high. For example, at the end of 2016, of the
estimated 1,140,400 people over the age of 12 living with HIV, 476,100 of them were black. In
2016, black people represented roughly 12% of the population, but they represented 42.4% of
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all new HIV infections (CDC, 2019a). Put differently, in 2016, the rate of new infections was
8.9 times higher among black people than among white people. These disproportionate trends
continued with respect to diagnosed HIV infections in 2018 (CDC, 2020a).
Black men who have sex with men (MSM) are particularly vulnerable—of the almost 39,000
people infected with HIV in 2016, black gay or bisexual men accounted for around 10,000 of
the infections, with about 8,300 Hispanic/Latino gay or bisexual men and 6,700 white gay or
bisexual men being infected. In 2016, Hispanics/Latinos represented 18% of the population
but accounted for 27% of HIV diagnoses. Black and Latino populations also have the highest
rates of undiagnosed HIV infection, stymieing those communities’ ability to get treated for the
infection. Black women are also disproportionately impacted—in 2016, their rate of new
infections was 15.1 times the rate for white females. Geographically, rates of new infection in
2016 were highest in the South (CDC, 2019a). The Deep South has also had the highest HIV
death rates (Reif, Safley, McAllaster, Wilson, & Whetten, 2017).
In addition to racial and geographic disparities, MSM continue to bear the brunt of the
epidemic. In 2016, 68% of all new infections occurred as a result of male-to-male sexual
contact, with 84% of all male infections resulting from male-to-male sexual contact. Similarly,
among diagnosed HIV infections in 2018, 69% were among MSM. (CDC, 2020a). As noted,
among MSM, racial disparities persist. From 2010 to 2016, new, annual HIV infections among
white MSM decreased, remained stable among black MSM, and increased among Latino MSM
(CDC, 2019a).
As highlighted, the decrease in the overall number of new infections in the United States has
plateaued. More dramatic progress is curtailed, in part, by the so-called treatment cascade or
care continuum. The treatment cascade refers to the fact that, as of 2016, of the million plus
people living with HIV in the United States, only about 86% (or 1 in 7) have actually been
diagnosed with the virus, and only 64% were in receipt of care (defined as at least one CD4 or
viral load test in a year-long period). Only 49% were retained in care (defined as two or more
CD4 or viral load tests at least 3 months apart in an annual period). Ultimately, only 53% of all
people living with HIV had achieved viral suppression, which is defined as the achievement of
very low levels of HIV in someone’s blood (CDC, 2019c).
Viral suppression is critical to the health and well-being of someone living with HIV—that is,
critical to their successful treatment. In addition, when the level of virus is suppressed enough
that it becomes undetectable, HIV is also untransmittable sexually from someone carrying the
disease to a sexual partner. As explained by multiple national and international public health
authorities, U = U—undetectable = untransmittable (Bruner, 2019). Therefore, treatment of
people with HIV is critical in the fight to stop its spread—a concept known as “treatment as
prevention” (Office of National AIDS Policy [ONAP], 2015). Indeed, according to an analysis
published in 2019, about 80% of new infections in the United States in 2016 were transmitted
from the roughly 40% of people living with HIV who either did not know of their infection or
who had been diagnosed but were not receiving care (Zihao, Purcell, Samson, Hayes, & Hall,
2019). Similarly, according to an analysis published in 2015, 9 in 10 new infections in 2009
came from people that either had not been diagnosed or had been diagnosed but were not
retained in care (Skarbinski et al., 2015). In other words, treatment and prevention are
intimately linked and if the disease is to be stopped from spreading, it is essential that those
already living with HIV be diagnosed and treated.
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Therefore, to the extent that the slope of the treatment cascade remains extreme—with only
half of people living with HIV virally suppressed—the ability of the disease to spread remains
very real. Based on this relationship between treatment and prevention, the Joint United
Nations Programme on HIV and AIDS (UNAIDS) set the ambitious 90-90-90 goal to be
achieved by 2020—90% of people living with HIV will know their status, at least 90% all
people diagnosed will receive sustained antiretroviral therapy, and 90% of all those receiving
antiretroviral therapy will have achieved viral suppression (UNAIDS, 2017). However, while
progress has been made toward the goal, achieving the 90-90-90 benchmarks by 2020 now
seems out of reach.

Two Steps Forward: The Reasons for Progress
The progress that has occurred is the result of tireless activism and education, innovative
public health strategies, antidiscrimination law reform, growing recognition that treatment of
people living with HIV is an important component in the fight to prevent the disease from
spreading, and the deployment of important medical advances.

Awareness and Education
HIV is a highly preventable disease. Informing people about how HIV is transmitted, how it is
not transmitted, and how to prevent transmission has been critical in the battle to stem the
tide of the epidemic. Educating the public about the disease has helped people protect
themselves, and it has also helped to decrease stigma and misunderstanding regarding those
living with the disease. Most commonly, people contract HIV through anal or vaginal sex
without use of a condom with someone who is HIV-positive but does not have an undetectable
viral load or through sharing a needle or syringe for injection drug use with someone who is
HIV-positive. HIV cannot be spread through casual contact, such as sharing a toilet seat,
sharing a drink, or kissing (CDC, 2019d). The use of condoms as a means of preventing the
spread of HIV during sex is highly effective (Henn, 2018). Furthermore, as is discussed in
more detail, the daily implementation of so-called pre-exposure prophylaxis (PrEP)—taking a
particular antiretroviral (ARV) medication—by someone who does not have HIV can also
dramatically reduce the risk that the person taking PrEP will contract HIV through
unprotected sex.
However, despite widespread efforts to educate the public about how HIV is spread, is not
spread, and can be prevented, certain myths stubbornly persist. According to a survey by the
Kaiser Family Foundation (KFF) in 2012, one third of Americans surveyed harbored at least
one misconception about HIV transmission. For example, 27% of those surveyed did not know
that HIV cannot be transmitted through sharing a drinking glass (Washington Post/KFF, 2012).
Moreover, according to a 2019 KFF poll, only 42% of the public were aware of PrEP, the
prescription medication that can dramatically lower the risk of getting HIV. Only 15% of the
public were aware that the use of antiretroviral (ARV) drugs to treat people with HIV was also
very effective at preventing the spread of the virus—the aforementioned concept of
“treatment as prevention” (Kirzinger, Lopes, Wu, & Brodie, 2019). As discussed, when an
individual undergoes ARV treatment and their viral load becomes undetectable, the virus is
then untransmittable to others sexually.
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These statistics underscore the continued need for education, awareness, and publicity
regarding the contours of the HIV epidemic. According to the 2012 KFF survey, visibility of the
epidemic had decreased meaningfully compared to the prior decade, confirming that renewed
efforts, funding, and vigilance are needed with regard to HIV education (Washington Post/
KFF, 2012).

Testing
Testing remains another critical first line of defense for treatment and prevention of the
disease. It stands to reason that, without testing, diagnosis may be delayed, limiting the
initiation of early ARV treatment that may reduce morbidity and mortality and simultaneously
reduce the risk of further HIV transmission. Moreover, people who are not aware that they
have HIV may not take steps to prevent the spread of the disease to others and may, for
example, continue to engage in unprotected sex.
Consequently, in 2006, the CDC began recommending that all adults (not just those deemed to
be engaging in high-risk behavior) who visit their healthcare provider be provided with socalled routine “opt-out testing,” allowing for consent as part of a general laboratory consent
form unless the patient declines, rather than a separate, specific “opt-in” consent to HIV
testing (Branson et al., 2006). Consequently, nearly every state has removed any requirement
for a separate consent to HIV testing. The change in policy was designed to increase the
number of people being tested—and therefore diagnosed and treated as soon as possible—at
the same time that it reduced stigma associated with HIV by no longer singling it out as a
somehow distinct, particularly significant, kind of laboratory test. Those engaged in behavior
putting them at higher risk of contracting HIV, such as men who have unprotected sex with
other men of unknown status and people who inject drugs (PWID), are advised to seek testing
more frequently—at least once a year (Branson et al., 2006). To be clear, although HIV
disproportionately impacts MSM relative to other groups, roughly 90% of queer men do not
have HIV and, as Robinson and Frost emphasized, MSM identity is a “weak proxy for being
HIV positive” (Robinson & Frost, 2018). Put differently, it is certain behavior (e.g.,
unprotected sex with partners of unknown status), not an MSM identity in and of itself, that
puts an individual at higher risk. Nevertheless, the CDC recommends that sexually active
MSM be screened at least annually, and perhaps more frequently, considering the patient’s
individual risk factors (DiNenno et al., 2017).
However, despite the CDC’s 2006 revised recommendations for more routine, opt-out testing,
according to an analysis released by the CDC in 2018, only 39.6% of adults surveyed had ever
been tested for HIV and only 62.2% of those reported to have engaged in HIV-related risk
behaviors over the preceding 12 months were ever tested for HIV. Moreover, the percentage
of persons ever tested and the interval since their last test remained unchanged between 2006
and 2016, suggesting that HIV screening frequency for those at risk for HIV has not improved
meaningfully since 2006—the year the CDC announced its more aggressive testing guidelines
(Pitasi et al., 2018). Similarly, according to a 2014 survey conducted by KFF, only about half of
US adults had ever been tested for HIV, with only 16% being tested in the year prior to the
survey (KFF, 2014). According to the CDC, the continued struggles to, in effect, enact
universal testing suggest that efforts need to be taken to expand testing in nonclinical settings
through, for example, social network strategies and home testing.
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Fortunately, accurate and increasingly accessible testing techniques continue to be developed.
The most accurate kinds of tests are clinical/laboratory blood tests that use the presence of
anti-HIV antibodies, HIV viral proteins, or viral RNA (or some combination) to diagnose HIV
infection. Importantly, even the widely used laboratory tests have what is called a “window
period”—a period of time after exposure where the test is unable to determine whether or not
a person has been infected. Put differently, it is impossible to detect HIV immediately after
infection—even in a clinical setting (DHHS, 2018). The range of the window period varies
depending on the specific kind of test performed and each individual’s response to the virus,
but generally speaking if a person is clinically tested 3 months after exposure and the test is
negative, there is a high degree of confidence that the person is not infected with HIV. If the
person is tested within 3 months of potential exposure and the result is negative, it is
recommended that the person be retested after 3 months have elapsed since exposure to
confirm the negative result. Clinical test results are usually available within a few days to a
few weeks after testing.
In addition to laboratory blood tests, in 2012 the FDA approved an in-home HIV test kit—the
OraQuick In-Home HIV test. This test uses an oral swab sample to provide results within 20
minutes. Because this oral, in-home test is less accurate than laboratory blood tests, results
should be confirmed with follow-up laboratory testing. However, the in-home test does provide
a more accessible form of testing for those unable to seek, or deterred from seeking,
laboratory blood testing and is one potential gateway for increasing universal testing outside
of the clinical setting (CDC, 2020c).

Prevention
While testing is key to the initiation of treatment and is an important tool for further
prevention, prevention is not just the responsibility of those already diagnosed with HIV. It is
everyone’s responsibility, and there are an increasing number of scientifically proven methods
that can be used to decrease the chances of transmission.

Condoms
Condoms—when used consistently and correctly—are a highly effective way of preventing the
transmission of HIV and other sexually transmitted diseases (Henn, 2018). In fact, when used
consistently and correctly, penis condoms are the only contraceptive that provides protection
against both pregnancy and most sexually transmitted diseases, including HIV. Moreover, they
are an incredibly cost-effective form of prevention and, of course, significantly less expensive
for individuals and governments than the cost of HIV antiretroviral treatment.
Notwithstanding condoms’ efficacy and importance, studies continue to suggest that condom
use remains spotty at best (Copen, 2017). As such, the CDC endorses structural-level condom
distribution programs that include wide distribution of free condoms accompanied by social
market campaigns promoting and normalizing condom use, with more targeted, high-intensity
risk-reduction interventions for individuals engaged in higher risk activities. Overall, the CDC
emphasizes that condom distribution programs should aim to make condoms available,
accessible, and acceptable (CDC, 2019e).
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PrEP
In addition to condom use, daily use of PrEP can reduce the risk of getting HIV through sex by
over 90%. While PrEP is less effective at preventing the spread of HIV through injection drug
use, it can still reduce the risk of HIV by 70%. Importantly, PrEP does not prevent other
sexually transmitted diseases or pregnancy, and so it should be combined with condom use
(CDC, 2019b). Truvada was first approved by the Food and Drug Administration (FDA) for use
as PrEP in adults in 2012, and for anyone—including adolescents—weighing 35 kg or more in
2018. A second drug called Descovy was approved by the FDA for use as PrEP for those
weighing 35 kgs or more in 2019 (though Descovy is not indicated for people at risk of HIV
from receptive vaginal sex). Federal guidelines are that prescription of PrEP is indicated for
people at high risk of HIV, including, among others: (a) anyone who is HIV-negative and in an
ongoing relationship with an HIV-positive partner, (b) gay or bisexual men not in a mutually
monogamous relationship with an HIV-negative person and who have had anal sex without
using a condom in the last 6 months, (c) heterosexual men or women who do not regularly use
condoms during sex with partners of unknown HIV status who are at substantial risk of HIV
infection, and (d) people who have injected drugs in the past 6 months while sharing injection
equipment (CDC, 2019b)
Based on these behavioral risk factors, the CDC estimates that more than 1 million Americans
have indications for PrEP prescriptions. According to a study published by the CDC’s Division
of HIV/AIDS Prevention in 2018 based on 2015 data, of the 1.1 million adults with indications
for PrEP, over 800,000 of them were MSM, over 500,000 were black, and over 280,00 were
Latino (Smith, Van Handel, & Grey, 2018).
However, despite PrEP’s efficacy and promise, PrEP uptake has—overall—been quite limited.
For example, in 2016, according to some estimates, only about 77,000 people were using PrEP
in the United States, notwithstanding that over 1 million people’s behavior suggested they
should take PrEP to prevent contracting HIV (AIDSVu, 2019). And while PrEP use has been
steadily increasing (for example, according to one estimate, use increased by about 30% each
year from 2016 to 2018), access to PrEP remains extremely uneven and limited in part
because of its cost and disproportionate lack of healthcare coverage generally for
marginalized communities. For example, communities of color and Southern states continue
to have disproportionate need for PrEP, but penetration of PrEP in these communities has
been limited (CDC, 2018b; Ojikutu et al., 2018). Similarly, notwithstanding that women
account for one of every five new HIV diagnoses, PrEP uptake among women (especially black
women) has been very low (Bradley & Hoover, 2019).
As Smith et al. (2018) concluded, “Urgent scaling up of PrEP delivery for blacks (in all
transmission risk groups) is the highest priority, both because of the high number and
proportion estimated to have indications for PrEP and because of their current very low
utilization of it.” The Smith study also confirmed that “MSM (of all race/ethnicities) remain a
priority for PrEP delivery” (Smith et al., 2018). Barriers to PrEP uptake and saturation include
insufficiently effective communication and education by public health authorities to indicated
populations on the drug’s existence, efficacy, and availability; insufficient education of
healthcare providers on how to identify patients who may benefit from PrEP; and cost of both
the medication and associated healthcare visits and labs (AIDSVu, 2018).
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A monthly prescription for Truvada can cost as much as $2,000, and although many insurers
and Medicaid cover the drug when it is prescribed, a person still requires insurance and
access to a provider willing to prescribe PrEP. As such, the CDC has begun providing targeted
funding to health departments and community-based organizations to expand access for those
indicated for PrEP. The CDC has also issued clinical guidelines to help healthcare providers
properly identify those in need of a PrEP prescription. The FDA approved a generic version of
Truvada manufactured by Teva Pharmaceuticals in 2017, and it will be available on the market
in the later part of 2020 (Straube, 2019). However, time will tell whether this has a dramatic
impact on the price of PrEP in the United States, because competition will still be limited to
just two manufacturers. In addition, in May 2019, Truvada manufacturer Gilead announced an
agreement with the U.S. Department of Health & Human Services (DHHS) to donate PrEP for
up to 200,000 uninsured people for 11 years (DHHS, 2019d). In another positive development,
in June 2019, the U.S. Preventative Services Task Force (USPSTF) gave PrEP an “A”
recommendation, finding convincing evidence that PrEP is of substantial benefit in reducing
HIV transmission in persons at high risk of infection (USPSTF, 2019). Consequently, under the
Affordable Care Act (ACA), individuals on private insurance who are prescribed PrEP have a
compelling argument that PrEP constitutes a preventative services which must be covered. In
short, while certain steps are being taken to make PrEP more accessible, distribution to those
in critical need remains relatively limited.

Syringe and Needle Exchanges
As highlighted by the outbreak of HIV among PWID in Scott County, Indiana, in 2014, sharing
needles and syringes for drug use remains a prevalent form of HIV transmission (Gonsalves &
Crawford, 2018). PWID account for about 1 in 10 HIV diagnoses in the United States (Wejnert
et al., 2016). As such, clean syringe and needle exchanges represent an important form of
harm reduction that can help prevent the spread of HIV among PWID, such as the outbreak
that occurred in Indiana. While the CDC recognizes that sterile needle and syringe exchange
programs are an important component of a comprehensive effort to prevent the spread of HIV,
federal funding for such programs is limited. Although federal funds can—upon request—be
used by state and local health departments for components of a comprehensive syringe
services program, the funds cannot be used to purchase sterile needles or syringes that will
be used for illegal injection drug use. At times, the CDC has called for an increase in support
for syringe service programs, particularly in rural areas where the risk of outbreak from
injection drugs is high and provision of harm reduction services is low (CDC, 2020b; Wejnert
et al., 2016).
Indeed, as emphasized by the CDC, there is empirical evidence from certain states and
localities that have implemented needle and syringe exchange programs that such programs
are both effective at reducing the rate of HIV infection among PWID and are cost-effective
(CDC, 2016). According to one study of New York City, the initiation of needle exchanges
helped decrease the prevalence of HIV among PWID from 50% in 1992 (when such programs
were first legalized/initiated at scale) to 17% in 2002 (Des Jarlais, 2005). In addition to directly
decreasing the risk of transmission from used needles and syringes, exchange programs can
also serve as intervention points for other public health harm-reduction methods, including
condom distribution and HIV testing (CDC, 2020b; Wejnert et al., 2016).
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Post-Exposure Prophylaxis (PEP)
The most effective techniques for preventing transmission of HIV are those that actually
prevent exposure to fluids containing the virus (for example, condoms or needle exchanges) or
those that are in place prior to exposure in order to prevent the virus from taking hold (for
instance, PrEP). However, even if someone is exposed to body fluids known to be HIV-positive
and the exposure represents a substantial risk of transmission, if certain antiretroviral drugs
are first taken within 72 hours of the initial exposure and are continued as prescribed for 28
days, infection may be prevented. This prevention technique is known as post-exposure
prophylaxis (PEP) and is designed only for emergencies as a prevention measure of last resort
(CDC, 2018c, 2019f).

Treatment and Treatment as Prevention
In addition to prevention techniques described above, incredible advances in medicine and
science—spurred on by HIV/AIDS activism—have enabled several forms of effective medical
treatments for an HIV infection if it is contracted. Highly effective antiretroviral drugs have
been invented (or repurposed) to fight the development and replication of HIV in the human
body. By interfering with the virus’s reproduction, antiretroviral drugs help the immune
system to remain strong, preventing HIV from causing AIDS (the syndrome characterized by a
potentially fatally weak immune system).
Different antiretroviral drugs attack different aspects of HIV and are often prescribed in
combinations of two or more drugs, deemed ART (antiretroviral therapy) or HAART (highly
active antiretroviral therapy). Colloquially, combined drug therapy is sometimes referred to as
a drug “cocktail.” DHHS recommends that individuals diagnosed with HIV begin treatment
with ART as soon as possible after diagnosis (DHHS, 2019b).
There are at least six general categories of HIV antiretroviral drugs, but the principal
categories are nucleoside reverse transcriptase inhibitors (NRTIs), which block an enzyme
called reverse transcriptase that HIV needs to replicate itself; non-nucleoside reverse
transcriptase inhibitors (NNRTIs), which bind to and alter reverse transcriptase; protease
inhibitors (PIs), which block protease, another enzyme HIV needs to replicate itself; fusion
inhibitors, which block HIV from entering CD4 immune system cells; and integrase inhibitors,
which block integrase, yet another enzyme HIV needs to copy itself (DHHS, 2019c).
For those with access to HAART, these medicines have transformed HIV from a death
sentence to a chronic condition that can be managed, allowing people with HIV to lead long,
fulfilling lives. And, as discussed, treatment of HIV not only is critical to saving the lives of
those already infected, but also is actually a key prevention technique, because when a
person’s viral load is undetectable as a result of HAART, the person doesn’t transmit the virus
to others sexually. In other words, treatment of HIV prevents the spread of HIV. The Obama
Administration’s National HIV/AIDS Strategy for the United States recognized this important
link and that increasing access to treatment was critical to HIV prevention (ONAP, 2010,
2015).
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But make no mistake. There was nothing inevitable about the creation of—and access to—
antiretroviral drugs in response to the HIV epidemic. When the epidemic first emerged in the
United States in the 1980s, the federal government was slow to respond, allowing AIDS to
become the leading cause of death for adults between the age of 25 and 44 by 1995 (Altman,
1995). But because of HIV activists, the federal government eventually accelerated its efforts,
fast-tracking approval of certain medications and increasing access to them. The government
and leaders at the National Institutes of Health (NIH) have openly acknowledged the
important role of HIV/AIDS activists in advancing the public health response to the epidemic
(NIH, 2009).
In particular, certain programs—such as the Ryan White HIV/AIDS Program—have helped
expand access to life-saving medication. Initially passed in 1990 and funded at varying levels
since by the federal government, the Ryan White HIV/AIDS Program is the largest federal
program specifically targeting people living with HIV, and the third largest overall source of
federal funding for HIV care, following Medicare and Medicaid (Health Resources & Services
Administration [HRSA], 2019; KFF, 2019). The program provides grants to states and localities
for the provision of comprehensive medical care and support services for people living with
HIV. As of 2019, more than half a million people received services through the program and,
for FY 2019, the program was funded at $2.3 billion. An important component of the Ryan
White Program is the AIDS Drug Assistance Program, which provides FDA-approved
antiretroviral medications to low-income people living with HIV who have limited or
insufficient health insurance coverage from Medicare, Medicaid, or private insurance. Even
with the enactment of the ACA in 2010, which expanded access to insurance for people living
with HIV by, among other mechanisms, lifting insurance prohibitions on pre-existing
conditions and by Medicaid expansion in certain states, the Ryan White Program remains a
critical source of funding for HIV treatment and helps fill in important gaps in healthcare
coverage for people living with HIV (HRSA, 2019; KFF, 2019).
But despite the partial success of the ACA, Ryan White, Medicare, and Medicaid in extending
healthcare and prescription drug treatment to people living with HIV, access to care remains
unequal. The divergent progress in combatting the spread and treatment of HIV is not an
accident. However, as discussed in the following section, it is the predictable result of
different law and policy decisions that exacerbate and contribute to other social inequalities.

One Step Back: Current Policies and Practices Impeding Progress
Despite the tremendous progress that has been made since the outset of the HIV epidemic in
the 1980s, significant barriers to care remain. While the Obama Administration put forth a
comprehensive National HIV/AIDS Strategy focused on reducing HIV-related health inequities
and creating a more coordinated national response to the epidemic, the Trump Administration
remained largely silent on how to combat the spread of the disease for nearly 2 years,
negatively affecting prevention and treatment efforts (Cahill, 2019). For example, President
Trump never appointed a director of the Office of National AIDS Policy (ONAP), the White
House office responsible for coordinating the federal government’s efforts to combat HIV.
Similarly, over the course of 2017 and 2018, the members of the Presidential Advisory Council
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on HIV/AIDS (PACHA), which provides advice to the White House on HIV policy, either quit in
protest over the Trump Administration’s tepid response to HIV or were fired (PACHA was
reconstituted in March 2019; Johnson, 2019).
While President Trump announced a broad strokes recommitment to combatting HIV in his
2019 State of the Union Address and reconstituted PACHA in March 2019, details of the
Trump Administration’s approach are still emerging. The administration has promised to
develop and update the National HIV/AIDS Strategy developed by President Obama in 2020
(DHHS, 2019a). When President Trump announced his purported focus on HIV in February
2019, he created a goal of eliminating HIV in the United States by 2030 and subsequently
pledged roughly $300 million in additional funding for HIV prevention efforts in his FY 2020
budget. To reach its professed goal of a 75% reduction in infections over the next 5 years and
a 90% reduction over the next 10 years, the Trump Administration intends to target resources
toward so-called geographic hotspots, which have a disproportionate HIV burden, including
seven states and 48 counties, along with Washington, DC, and San Juan, Puerto Rico.
While this new attention and the targeting of resources at underserved areas are welcome
and are no doubt aided by devoted public servants continuing to work in the federal
government, several federal and state policies undermine the Trump Administration’s
professed goals. The continuation of multiple policies that stigmatize both HIV and those
associated with the virus discourage people from learning their status and getting treatment,
thereby allowing the disease to more easily spread from person to person. Moreover, more
generalized racial, economic, and regional healthcare disparities and barriers to healthcare
are impeding elimination of the virus, particularly for historically marginalized communities.
Put simply, while the Trump Administration is promising additional resources for HIV, they are
otherwise cutting healthcare for those in need—including populations disproportionately
impacted by the HIV epidemic.

HIV Discrimination and Stigma
From the early days of the HIV epidemic in the 1980s, public health authorities—including
President Reagan’s Presidential Commission on the Human Immunodeficiency Virus
Epidemic, recognized that if there were not legal prohibitions on discrimination against
individuals living with HIV, people would be deterred from coming forward to obtain testing
and care. According to the Commission, “fear of potential discrimination … will undermine
our efforts to contain the HIV epidemic and will leave HIV-infected individuals isolated and
alone” (Presidential Commission, 1988). The important recognition that discrimination
impedes public health has meant that people living with HIV have been protected in a variety
of contexts—including employment, public accommodations, public services, healthcare, and
housing—by several federal statutes, most prominently the Americans with Disabilities Act
and the Rehabilitation Act (Skinner-Thompson, 2018).
However, several important exceptions to the antidiscrimination principle persist. And, even
where legal protections are in place, often the protections are underenforced.
One visible context where antidiscrimination protections for people living with HIV have not
been robustly extended is military employment. While the Rehabilitation Act generally
prohibits employment discrimination on the basis of disability—including HIV—by federal
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government agencies, the Rehabilitation Act does not apply to military service members
(though the Rehabilitation Act has been extended to civilian personnel in the armed forces),
and the US military discriminates against individuals living with HIV in a couple of different
ways.
First, the Department of Defense prohibits HIV-positive individuals from enlisting in the
military, regardless of whether an individual is asymptomatic or otherwise healthy. Second,
active-duty personnel who test positive for HIV while in the military are prevented from being
appointed as an officer, are often subject to significant limitations on their deployment, and,
under the Trump Administration, face increased threats of discharge because of their HIV
status. Importantly, instances where individuals with HIV have been discharged or have been
deemed nondeployable on the basis of their HIV status alone, without consideration of their
health and fitness for duty, have come under increased legal scrutiny.
For example, in February 2019, in the decision in the case of Roe v. Shanahan (No. 1:18cv-1565, 2019 WL 643971 [E.D. Va. Feb. 15, 2019]), a federal district court judge concluded
the Air Force’s categorical policy of limiting the deployment of asymptomatic HIV-positive
service members likely violates the Equal Protection clause. According to the court,
categorical limitations on the ability of people living with HIV to serve are arbitrary, irrational,
and ignore scientific evidence that many whose HIV is treated with antiretroviral medications
are physically and mentally capable of performing all military duties required of them.
Similarly, the court concluded that instances where HIV-positive service members had been
discharged based solely on their HIV status, without individualized consideration of their
fitness for duty, were also likely arbitrary and unlawful. (This decision was affirmed on nonconstitutional grounds by the Fourth Circuit Court of Appeals in January 2020). Until each
branch of the US military ends policies that treat people living with HIV in categorical,
discriminatory ways, the military is perpetuating misinformation and stigma regarding HIV
and the ability of those living with it to live full lives.
The nation’s blood donation policy is another context where groups associated with HIV are
subject to discrimination. In 2015 and then again in April 2020, the FDA issued revised
guidance governing who can donate blood and who will be deferred from donating based on
the FDA’s conclusion that they pose a risk of donating HIV-infected blood (FDA, 2015). Prior to
2015, MSM were categorically and indefinitely deferred—or barred—from donating blood.
Pursuant to the 2015 revisions, men were not allowed to donate if they have had sex with
another man in the 12 months prior to the attempted donation. In the wake of the COVID-19
crisis and need for increased blood donations, the FDA further revised the guidance in 2020 to
provide that men are not allowed to donate if they have had sex with another man in the 3
months prior to the attempted donation. While an improvement, thousands of gay and
bisexual men who have sex regularly are still prevented from donating. While the policy now
bears a closer relationship to the “window period” during which an HIV infection may not be
detected, the policy is still irrational, fails to individually assess potential donors, and bars
men from donating even if, for example, they are in a monogamous longtime relationship and
both members of the partnership are seronegative (Skinner-Thompson, 2015).
In addition to stigmatizing gay and bisexual men, rather than focusing on conduct that puts
someone at risk of HIV and deploying individualized assessments of each potential donor’s
sexual practices (safe or not), the policy sends an inaccurate and misleading public health
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message. Rather than emphasizing that anyone—regardless of gender, sexuality, race, or
socioeconomic background—is at risk of contracting HIV if they engage in unprotected sex
with partners of unknown HIV status, the FDA policy puts undue emphasis and attention on a
group of people—gay and bisexual men—rather than risk behaviors and sexual precautions.
The policy contributes to misinformation regarding who is at risk and how HIV is spread,
undermining one of the key public health tools for combatting HIV—education on its
transmission. Furthermore, the policy ignores the fact that the blood supply is rigorously
screened and tested for HIV, meaning that the risk of contracting HIV through a blood
donation is incredibly small (Cohen, Feigenbaum, & Adashi, 2014; Skinner-Thompson, 2015).
Finally, there are examples where discrimination against people living with HIV persist
notwithstanding statutory legal prohibitions on that discrimination. As mentioned, federal
statutes, including the Americans with Disabilities Act, prohibit discrimination against people
living with HIV by places of public accommodation. This includes healthcare providers
(Lambda Legal, 2010). Access to healthcare is, of course, critically important for people living
with HIV. However, misinformation and stigma persist—even among healthcare providers—
resulting in too many examples where providers have refused equal service to people living
with HIV. In 2012, the U.S. Department of Justice (DOJ) initiated the Barrier-Free Health Care
Initiative, which sought to increase enforcement of the ADA’s protections for people living
with disabilities—including HIV—in the healthcare setting (DOJ, 2019). While the program led
to several settlements with healthcare providers who had refused to provide equal treatment
to patients with HIV, it is unclear whether the program meaningfully persists under the Trump
Administration.

Criminalization of HIV
Unfortunately, the use of criminal laws to police and punish those who have engaged in
activities that might have exposed others to a risk (sometimes a negligible risk) of HIV
transmission continues within the United States. Over half of the states have HIV-specific
criminal statutes. These statutes vary greatly, but many of them criminalize engaging in
sexual conduct with another person without disclosing that one has HIV, and some criminalize
sexual activities—such as oral sex—that pose a low risk of HIV transmission (Center for HIV
Law & Policy [CHLP], 2019; Wolf, 2018).
States have also relied on general criminal laws—such as attempted homicide or assault laws
—to prosecute people who have allegedly exposed others to HIV. Importantly, the criminal law
is often applied to HIV-positive people who engage in sexual conduct even if no actual
transmission of HIV occurs. Moreover, the law has been used to criminalize conduct even
when the risk of transmission is very low. For example, if a person uses a condom or has an
undetectable viral load, then the risk of transmission via sexual intercourse is very small. The
statutes also fail to consider that now—with PrEP—all parties to a consensual sexual
encounter can, if they are fortunate enough to have access to PrEP, protect themselves from
HIV transmission (CHLP, 2019).
Whether pursued under general criminal law or HIV-specific statutes, the criminalization of
HIV transmission has negative public health impacts. First, it discourages people from being
tested. Most criminal laws have some form of knowledge requirement. If a person does not
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know they are HIV positive, they may not be successfully prosecuted for potential
transmission. This creates a disincentive to being tested, because if you do not know your
status, you are less likely to be prosecuted for knowing transmission.
Second, when the criminal law is used to prosecute people living with HIV who engage in
activities that pose a low risk of transmission (such as using a condom during sex or an
individual with an undetectable viral load engaging in sex), the law perpetuates
misinformation regarding how HIV is transmitted.
Third, there is little to no evidence that criminalizing sexual conduct by someone who is HIVpositive actually deters people living with HIV from engaging in sexual conduct in the first
instance. That is, the criminal law does not appear deter HIV-positive individuals from having
sex. As explained by the 2015 Updated National HIV/AIDS Strategy, “HIV-specific [criminal]
laws do not influence the behavior of people living with HIV in those states where these laws
exist.” (ONAP, 2015).
Finally, like many criminal laws, HIV criminal laws disproportionately affect people already at
the margins of society and subject to overpolicing, including sex workers and people of color
(Ahmed, 2016; Ahmed, Kaplan, Symington, & Kismodi, 2011).
For these reasons, the National HIV/AIDS Strategy released by the Obama Administration
called for states to reexamine the use of criminal law to police potential transmission, noting
that the continued “existence and enforcement of these types of laws run counter to scientific
evidence about routes of HIV transmission” and may “undermine the public health goals of
promoting HIV screening and treatment” because such laws make people less willing to
disclose their status when they feel at greater risk of discrimination (ONAP, 2015).
Nevertheless, the application of criminal law to people living with HIV persists.

Healthcare Disparities and Access to Care
In addition to combatting HIV discrimination, stigma, and criminalization—and related
homophobia/transphobia and racism—more generalized healthcare disparities must be
eliminated in order to effectively combat HIV. Unfortunately, certain policies are impeding
greater healthcare access, including for people living with HIV or at higher risk of becoming
infected (Reif, Wilson, & McAllaster, 2017).
For instance, while the ACA ensured that people living with HIV could not be denied
insurance coverage for pre-existing conditions, required insurance plans to cover preventative
services like HIV testing, and expanded Medicaid eligibility to adults earning up to 138% of
the federal poverty level in those states that chose to expand Medicaid, the ACA’s full
potential for many people, including many people living with HIV, remains unfulfilled (Kates &
Dawson, 2017). In addition, the ACA’s future remains uncertain, as President Trump and
Republican allies continue to attempt to roll back the ACA in Congress, through executive
power, and in the courts.
The refusal of several states to take advantage of the ACA’s expanded income-eligibility level
for Medicaid (so-called “Medicaid expansion”) is a good example. Medicaid is the source of
insurance coverage for the largest number of non-elderly adults living with HIV, but its reach
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has been blunted because, as of the Spring 2020, 14 states have chosen not to participate in
Medicaid expansion. Most of these states are in the southeast, where HIV is having a
disproportionate impact. Because of these states’ refusal to expand Medicaid eligibility, more
than 2 million people fall into the so-called coverage gap—meaning they make too much to
qualify for Medicaid under their state’s rules, but not enough to qualify for the ACA’s
marketplace insurance tax credits (Garfield, 2020). According to an analysis by the KFF, in
2015, in non-expansion states, the rate of people living with HIV who were uninsured was
19%, versus just 5% in states that had expanded Medicaid eligibility (Dawson & Kates, 2019).
So, while the ACA has led to a significant overall increase in insurance coverage for people
with HIV (many through Medicaid), its impact has been mitigated by the failure to expand
Medicaid in every state.
In short, while President Trump’s professed commitment in 2019 to fighting HIV is a positive
development, the Trump Administration’s broader attacks on the ACA and the perpetuation of
stigma and discrimination toward people living with HIV, queer communities, and
communities of color are undermining HIV treatment and prevention efforts.

Conclusion
President Obama’s National HIV/AIDS Strategy provided as its vision that “[t]he United States
will become a place where new HIV infections are rare, and when they do occur, every person,
regardless of age, gender, race/ethnicity, sexual orientation, gender identity, or socioeconomic circumstance, will have unfettered access to high quality, life-extending care, free
from stigma and discrimination.” These are important goals—goals that should drive the law
and policy of the United States. While progress has been achieved toward achieving these
goals, substantial barriers remain, including HIV stigma and discrimination, criminalization of
HIV, homophobia, transphobia, racism, and unequal access to healthcare generally and HIV
care specifically. If political capital, resources, and public attention are devoted to dismantling
these barriers, then the vision of an HIV-free United States can become a reality.
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Notes
1. Nothing in this article constitutes medical or legal advice, and before initiating any medical treatment, please
consult a healthcare provider. The information and statistics contained herein were drawn primarily from sources
publicly available by mid-2019, when this article was written, with some updates in spring 2020.

Related Articles
Public Opinion and Religion: Gay Rights in the United States
Theoretical Perspectives on Subnational Public Policy and LGBT Law
HIV/AIDS Politics and Policy in Eastern Europe and Central Asia
LGBT People as a Relatively Politically Powerless Group

Page 19 of 19

PRINTED FROM the OXFORD RESEARCH ENCYCLOPEDIA, POLITICS (oxfordre.com/politics). (c) Oxford University Press USA, 2020. All
Legal Notice Rights Reserved. Personal use only; commercial use is strictly prohibited (for details see and ).
Privacy Policy <https://global.oup.com/privacy>
Subscriber: OUP-Reference Gratis Access; date: 01 November 2020

